Literature DB >> 7516268

Disturbed immunoregulatory properties of the neuropeptide substance P on lymphocyte proliferation in HIV infection.

M J Covas1, L A Pinto, R M Victorino.   

Abstract

The neuropeptide substance P (SP) is known to increase cell-mediated immune responses in animal models and healthy subjects. Several studies have suggested an involvement of neuropeptides in the immunopathogenesis of some diseases. The study of the immunomodulatory effects of neuropeptides, namely SP, may represent a model for the analysis of immunoregulatory defects in HIV infection at the level of the interaction between the immune and nervous systems, both of which are known to be affected by the virus. In the present study, we investigate the possibility of a disturbance in the immunomodulatory properties of SP in HIV infection by analysing the effects of SP (10(-10)-10(-6) M) on the lymphocyte proliferative responses to concanavalin A (Con A) and phytohaemagglutinin (PHA) assessed by 3H-thymidine incorporation in peripheral blood lymphocytes from 34 HIV-infected patients (16 asymptomatic (ASY)/persistent generalized lymphadenopathy (PGL); 18 ARC/AIDS) and in 37 healthy subjects. In ASY/PGL HIV-infected patients, SP 10(-7) M was identified as the concentration inducing the maximal increase in the lymphocyte responses to Con A and PHA, similarly to what was observed in healthy subjects. In ARC/AIDS patients, SP appeared to inhibit the mitogenic responses, particularly those induced by Con A, in contrast to the effects found either in healthy subjects or in ASY/PGL patients. These results suggest the existence of an alteration in the in vitro immunomodulatory properties of SP in ARC/AIDS patients compared with healthy subjects and ASY/PGL patients. In conclusion, the unexpected finding of an inhibitory effect of SP on lymphocyte proliferation from ARC/AIDS patients justifies further investigation of the neuropeptide-dependent immunoregulatory systems in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516268      PMCID: PMC1534556          DOI: 10.1111/j.1365-2249.1994.tb06039.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme.

Authors:  L H Wang; S Ahmad; I F Benter; A Chow; S Mizutani; P E Ward
Journal:  Peptides       Date:  1991 Nov-Dec       Impact factor: 3.750

2.  Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements.

Authors:  D A Nio; R N Moylan; J K Roche
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

Review 3.  The immunopathogenesis of human immunodeficiency virus infection.

Authors:  G Pantaleo; C Graziosi; A S Fauci
Journal:  N Engl J Med       Date:  1993-02-04       Impact factor: 91.245

4.  Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells.

Authors:  P K Peterson; B Sharp; G Gekker; C Brummitt; W F Keane
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

5.  Substance P modulates antigen-induced, IFN-gamma production in murine Schistosomiasis mansoni.

Authors:  A M Blum; A Metwali; G Cook; R C Mathew; D Elliott; J V Weinstock
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

6.  Selective decrease of CD26 expression in T cells from HIV-1-infected individuals.

Authors:  M V Blazquez; J A Madueño; R Gonzalez; R Jurado; W W Bachovchin; J Peña; E Muñoz
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

7.  Observation of the effect of substance P on human T and B lymphocyte proliferation.

Authors:  L P Zhu; D Chen; S Z Zhang; S L Liu
Journal:  Immunol Commun       Date:  1984

8.  Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects.

Authors:  G Vanham; L Kestens; I De Meester; J Vingerhoets; G Penne; G Vanhoof; S Scharpé; H Heyligen; E Bosmans; J L Ceuppens
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-07

9.  [Changed levels of substance P and somatostatin in HIV-positive children].

Authors:  C Azzari; M E Rossi; M Resti; A L Caldini; L Lega; L Galli; E Fico; A Vierucci
Journal:  Pediatr Med Chir       Date:  1992 Nov-Dec

10.  Intraneuronal substance P contributes to the severity of experimental arthritis.

Authors:  J D Levine; R Clark; M Devor; C Helms; M A Moskowitz; A I Basbaum
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

View more
  3 in total

1.  Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.

Authors:  R A Tripp; D Moore; J Winter; L J Anderson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.

Authors:  Lia M Haynes; Joelyn Tonkin; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 3.  The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders.

Authors:  M Brittany Johnson; Ada D Young; Ian Marriott
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.